Atossa Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Atossa Therapeutics kazanç ve gelirinin sırasıyla yıllık 40.1% ve 83% oranında artması tahmin edilirken, EPS'nin yıllık 50.8% oranında büyümesi bekleniyor.

Anahtar bilgiler

40.1%

Kazanç büyüme oranı

50.8%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.6%
Gelir büyüme oranı	83.0%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	12 Dec 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Mar 07

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Nov 08

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

Apr 26

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Jan 09

Atossa Therapeutics: Still Gets An 'Incomplete' Rating

Oct 11

We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Sep 25

Atossa Therapeutics GAAP EPS of -$0.05

Aug 08

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

May 12

A First Assessment On Atossa Therapeutics

Dec 10

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 02

Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World

Sep 22

Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business

Jul 17

Atossa Therapeutics: Hope Springs Eternal

Jun 30

Atossa Therapeutics to be included in the Russell 2000, 3000 indexes

Jun 16

Atossa reaches a two-year high ahead of data readout for breast cancer therapy

Jun 07

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Apr 02

Atossa updates on single-patient study for Endoxifen

Feb 04

Atossa halts Endoxifen breast cancer study after positive data

Feb 02

Atossa Therapeutics prices ~$25M direct offering, stock -23% PM

Jan 06

Atossa Therapeutics prices $14M registered direct offering

Dec 17

We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 10

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:ATOS - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	N/A	-37	-20	-26	3
12/31/2025	N/A	-32	-9	-27	4
12/31/2024	N/A	-27	N/A	-24	4
9/30/2024	N/A	-27	-20	-20	N/A
6/30/2024	N/A	-26	-19	-19	N/A
3/31/2024	N/A	-30	-19	-19	N/A
12/31/2023	N/A	-30	-21	-21	N/A
9/30/2023	N/A	-30	-20	-20	N/A
6/30/2023	N/A	-32	-21	-21	N/A
3/31/2023	N/A	-28	-23	-23	N/A
12/31/2022	N/A	-27	-21	-21	N/A
9/30/2022	N/A	-24	-20	-20	N/A
6/30/2022	N/A	-21	-18	-18	N/A
3/31/2022	N/A	-22	-17	-17	N/A
12/31/2021	N/A	-21	-16	-16	N/A
9/30/2021	N/A	-28	-16	-16	N/A
6/30/2021	N/A	-26	-16	-16	N/A
3/31/2021	N/A	-23	-13	-13	N/A
12/31/2020	N/A	-22	-12	-12	N/A
9/30/2020	N/A	-13	-11	-11	N/A
6/30/2020	N/A	-13	-10	-10	N/A
3/31/2020	N/A	-16	-10	-10	N/A
12/31/2019	N/A	-17	-9	-9	N/A
9/30/2019	N/A	-17	-9	-9	N/A
6/30/2019	N/A	-17	-9	-9	N/A
3/31/2019	N/A	-25	-9	-9	N/A
12/31/2018	N/A	-23	-9	-9	N/A
9/30/2018	N/A	-23	-8	-8	N/A
6/30/2018	N/A	-22	N/A	-8	N/A
3/31/2018	N/A	-11	N/A	-7	N/A
12/31/2017	N/A	-11	N/A	-7	N/A
9/30/2017	N/A	-11	N/A	-6	N/A
6/30/2017	N/A	-9	N/A	-4	N/A
3/31/2017	N/A	-6	N/A	-4	N/A
12/31/2016	N/A	-6	N/A	-5	N/A
9/30/2016	0	-6	N/A	-8	N/A
6/30/2016	0	-10	N/A	-12	N/A
3/31/2016	0	-12	N/A	-14	N/A
12/31/2015	0	-13	N/A	-14	N/A
9/30/2015	0	-13	N/A	-13	N/A
6/30/2015	0	-13	N/A	-12	N/A
3/31/2015	0	-13	N/A	-11	N/A
12/31/2014	0	-12	N/A	-11	N/A
9/30/2014	0	-12	N/A	-10	N/A
6/30/2014	0	-12	N/A	-10	N/A
3/31/2014	0	-11	N/A	-10	N/A
12/31/2013	1	-11	N/A	-9	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ATOS önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: ATOS önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: ATOS önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: ATOS gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: ATOS gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ATOS 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/26 11:19
Gün Sonu Hisse Fiyatı	2024/12/26 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Atossa Therapeutics, Inc. 9 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Edward Woo	Ascendiant Capital Markets LLC
Louise Chen	Cantor Fitzgerald & Co.
Pooya Hemami	Edison Investment Research

Atossa Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 7.7% to US$5.83

Forecast to breakeven in 2026

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2026

Price target decreased by 7.5% to US$4.63

Recent updates

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z-Endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Atossa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Price target increased by 7.7% to US$5.83

New major risk - Revenue and earnings growth

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go

Atossa Therapeutics Reports Positive Karisma-Endoxifen Trial Results

Atossa Therapeutics, Inc Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Atossa Therapeutics Grants Additional Patent Protection for Endoxifen

Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Forecast to breakeven in 2026

Atossa Therapeutics Completes Enrollment of 80Mg Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z)-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer

Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

No longer forecast to breakeven

Atossa Therapeutics, Inc. Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial

No longer forecast to breakeven

Atossa Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer

Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

New minor risk - Profitability

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient

New minor risk - Share price stability

Atossa Therapeutics Regain Compliance with Nasdaq Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Less than half of directors are independent

Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Forecast to breakeven in 2026

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

Atossa Therapeutics, Inc. Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

Atossa Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Insufficient new directors

Atossa Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

Atossa Therapeutics, Inc. Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

New minor risk - Share price stability

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) announces an Equity Buyback for $10 million worth of its shares.

Atossa Therapeutics, Inc. Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer

Atossa Therapeutics, Inc. Announces Executive Changes

Price target decreased by 7.5% to US$4.63

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Price target decreased to US$5.00

Price target decreased to US$5.00

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) agreed to acquire 19.99% equity in Dynamic Cell Therapies, Inc. for $5 million.

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) agreed to acquire 19.99% equity in Dynamic Cell Therapies, Inc. for $5 million.

Atossa Therapeutics, Inc. Appoints Richard Graydon as Interim Chief Medical Officer

Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate Its Phase 2 Study of Neoadjuvant (Z)-Endoxifen in Premenopausal Women with Er+/Her2- Breast Cancer

Atossa Therapeutics: Still Gets An 'Incomplete' Rating

Atossa Therapeutics Receives Letter from NASDAQ Regarding Minimum Bid Price Requirement

We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Atossa Therapeutics, Inc. Appoints Dr. Paul Wabnitz to its Scientific Advisory Board

Atossa Therapeutics GAAP EPS of -$0.05

Atossa Therapeutics, Inc. Announces Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

Insufficient new directors

Atossa Therapeutics, Inc. Announces Completion of Participants Enrollment in Part B of its Phase 1/2a Clinical Study of AT-H201 in Australia, Consisting of Multiple Ascending Dose Cohorts in Healthy Participants

Atossa Therapeutics, Inc., Annual General Meeting, May 13, 2022

No longer forecast to breakeven

Price target decreased to US$6.38